Bausch + Lomb Corporation reported second-quarter 2026 results on July 29, 2026, with revenue of $1.394 billion, representing a 9% increase as reported and 8% on a constant currency basis compared to the prior year period. The company posted a GAAP net loss of $14 million, or ($0.04) per share, against an adjusted EBITDA of $241 million. Management raised full-year 2026 revenue guidance to $5.44 billion–$5.54 billion and adjusteded EBITDA excluding acquired IPR&D guidance to $1.025 billion–$1.075 billion, citing broad-based growth across Surgical and Pharmaceuticals segments. The company also announced positive top-line results from a pivotal clinical study for its investigational enVista Beyond intraocular lens. Bausch + Lomb operates in the eye health industry, manufacturing contact lenses, surgical devices, and pharmaceuticals.
